Literature DB >> 28542714

Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.

Rie S Bech1,2, Kasper L Nielsen3, Thomas S Larsen4, Hans H Bentzen5, Line S Lynggaard5, Trung H Do6, Peter Braendstrup6, Jessica Brady7, N George Mikhaeel7, Karen Dybkaer2,3, Hans E Johnsen2,8, Paw Jensen2, Martin Bøgsted2,3, Tarec C El-Galaly2.   

Abstract

Entities:  

Keywords:  Follicular lymphoma; immunochemotherapy; maintenance therapy; non-Hodgkin lymphoma; rituximab

Mesh：

Substances：

Year:  2017        PMID： 28542714     DOI： 10.1111/bjh.14775

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study.

Authors:  C Madsen; M R Clausen; T L Plesner; A Pasanen; T Kuismanen; H H Bentzen; J M Jørgensen; I B Sillesen; B M Himmelstrup; D Rønnov-Jessen; K R Jensen; A M Pettinger; M Ludvigsen; S Leppä; F A d'Amore
Journal:  Blood Adv       Date:  2018-07-10

2.  Indolent lymphoma with composite histology and simultaneous transformation at initial diagnosis exhibit clinical features similar to de novo diffuse large B-cell lymphoma.

Authors:  Hanno Witte; Harald Biersack; Svenja Kopelke; Dirk Rades; Hartmut Merz; Veronica Bernard; Hendrik Lehnert; Niklas Gebauer
Journal:  Oncotarget       Date:  2018-04-13

3.  Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance.

Authors:  Hee Kyung Kim; Wonseok Kang; Dong Hyun Sinn; Joon Hyeok Lee; Won Seog Kim; Seok Jin Kim
Journal:  Korean J Intern Med       Date:  2019-04-04       Impact factor: 2.884

4.  Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China.

Authors:  Fenghua Gao; Tingting Zhang; Xia Liu; Zhenjie Qu; Xianming Liu; Lanfang Li; Lihua Qiu; Zhengzi Qian; Shiyong Zhou; Wenchen Gong; Bin Meng; Xiubao Ren; Xianhuo Wang; Huilai Zhang
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.